PARP1, BRCA1 and androgen receptor expression in triple-negative breast cancer patients treated with neoadjuvant chemotherapy

Rashed, Hayam E.; Monged, Randa E.; Nawar, Nashwa; Alattar, Ahmed Z.; Ayaz, Ahmed; Abdelhamid, Mohamed I.; Abd-Elaziz, Osama; Said, Noha Mohamed

doi:10.1016/j.senol.2021.08.002

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PARP1 nuclear expression was evaluated based on positive cells distribution. Positive PARP was defined as 1+ to 3+ nuclear staining in 5% of tumor cells [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

Prognostic Values of CD8+, PARP, and EGFR on Overall Survival in Patients with Triple-Negative Breast Cancer

Putri,

Haryono,

Brahma

et al. 2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: This study aimed to investigate the associations of CD8 +, PARP, and EGFR expressions with two-year survival in patients with triple-negative breast cancer (TNBC). Methods: A retrospective cohort study was conducted in a national cancer center. All patients aged 18 years diagnosed with TNBC (2013-2017) were included and followed for 24 months or until the patients were deceased. Kaplan-Meier survival function and Cox proportional hazard model were applied for the analyses. Results: The study population was followed for 24 months (2,692 person-months, N = 126). At the end of the follow-up, 27 patients were deceased. The two-year mortality rate was 10 per 1,000 person-month. Kaplan-Meier graphs showed that after approximately one year of follow-up, poorer survival was seen in patients with low CD8 +, positive PARP, and positive EGFR. The adjusted analysis found staging as the main predictor of overall survival in TNBC (HR = 7.20, 95% CI= 2.07 – 25.00). Conclusions: Patients with low CD8 +, positive PARP, and positive EGFR expressions seem to be associated with poorer overall survival in TNBC. After approximately one year of follow-up, higher survival was observed in patients with high CD8 +, negative PARP , and negative EGFR . Staging remains the main predictor of TNBC survival. Therefore, early detection and treatment of TNBC are essential to improve survival.

show abstract

“…PARP1 nuclear expression was evaluated based on positive cells distribution. Positive PARP was defined as 1+ to 3+ nuclear staining in 5% of tumor cells [ 19 ].…”

Section: Methodsmentioning

confidence: 99%